Home » FDA Approves Movement Disorder Drug From CNS Therapeutics
FDA Approves Movement Disorder Drug From CNS Therapeutics
CNS Therapeutics announced the FDA approval of Gablofen (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a new, easy-to-administer and cost-effective intrathecal baclofen treatment option.
CNBC
CNBC
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May